Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200 Day Moving Average – Should You Sell?

Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s share price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $26.57 and traded as high as $30.67. Celldex Therapeutics shares last traded at $29.48, with a volume of 650,121 shares.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Wolfe Research upgraded Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price target on the stock in a report on Monday, March 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st. Barclays lifted their price objective on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a research report on Wednesday, December 17th. The Goldman Sachs Group boosted their target price on Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a research note on Monday, March 2nd. Finally, Stifel Nicolaus restated a “buy” rating and set a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.45.

Celldex Therapeutics Stock Down 2.7%

The company has a market cap of $1.96 billion, a PE ratio of -7.58 and a beta of 1.17. The firm’s 50-day moving average is $27.27 and its 200-day moving average is $26.57.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $1.53 million. Celldex Therapeutics had a negative return on equity of 41.67% and a negative net margin of 3,446.88%. As a group, equities research analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Aster Capital Management DIFC Ltd purchased a new stake in shares of Celldex Therapeutics in the 3rd quarter worth approximately $26,000. Wilmington Savings Fund Society FSB bought a new stake in Celldex Therapeutics in the third quarter worth $42,000. Russell Investments Group Ltd. boosted its holdings in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 501 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Celldex Therapeutics in the third quarter worth $63,000. Finally, Strs Ohio purchased a new stake in shares of Celldex Therapeutics in the third quarter worth $75,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.